{
    "2019-01-03": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Why Johnson & Johnson Stock is Clearly Set to Rise Again",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "set to rise"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "3 Biopharma Stocks to Buy for Their Robust Dividend Yields",
                "features": {
                    "keywords": [
                        "Biopharma",
                        "dividend yields"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biopharma"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-20",
                "original_text": "Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "momentum"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-15",
                "original_text": "Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Phase 2b/3",
                        "clinical trial",
                        "JAK3 inhibitor",
                        "alopecia areata"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}